TSVT Stock Overview
A cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
2seventy bio, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.14 |
| 52 Week High | US$6.40 |
| 52 Week Low | US$2.78 |
| Beta | 1.7 |
| 1 Month Change | 0.96% |
| 3 Month Change | -37.82% |
| 1 Year Change | -20.30% |
| 3 Year Change | -89.87% |
| 5 Year Change | n/a |
| Change since IPO | -77.20% |
Recent News & Updates
Analysts Have Been Trimming Their 2seventy bio, Inc. (NASDAQ:TSVT) Price Target After Its Latest Report
Nov 15
There's No Escaping 2seventy bio, Inc.'s (NASDAQ:TSVT) Muted Revenues
Oct 03Recent updates
Analysts Have Been Trimming Their 2seventy bio, Inc. (NASDAQ:TSVT) Price Target After Its Latest Report
Nov 15There's No Escaping 2seventy bio, Inc.'s (NASDAQ:TSVT) Muted Revenues
Oct 032seventy bio, Inc.'s (NASDAQ:TSVT) Share Price Is Matching Sentiment Around Its Revenues
Jul 04Downgrade: Here's How Analysts See 2seventy bio, Inc. (NASDAQ:TSVT) Performing In The Near Term
May 112seventy Bio: Maximizing ABECMA's Potential To Fuel A Turnaround
Apr 03These Analysts Just Made A Massive Downgrade To Their 2seventy bio, Inc. (NASDAQ:TSVT) EPS Forecasts
Mar 072seventy bio, Inc. (NASDAQ:TSVT) Held Back By Insufficient Growth Even After Shares Climb 49%
Feb 06Here's Why We're Watching 2seventy bio's (NASDAQ:TSVT) Cash Burn Situation
Jan 172seventy bio, Inc. (NASDAQ:TSVT) Shares Fly 44% But Investors Aren't Buying For Growth
Dec 13Industry Analysts Just Made A Dazzling Upgrade To Their 2seventy bio, Inc. (NASDAQ:TSVT) Revenue Forecasts
May 05Industry Analysts Just Upgraded Their 2seventy bio, Inc. (NASDAQ:TSVT) Revenue Forecasts By 12%
Mar 212seventy bio, Inc. (NASDAQ:TSVT) Just Reported Annual Earnings And Analysts Are Lifting Their Estimates
Mar 19We're Keeping An Eye On 2seventy bio's (NASDAQ:TSVT) Cash Burn Rate
Oct 042seventy Bio: This Spinoff In The CAR-T Space Is Attractive
Sep 082seventy bio Prospects
Aug 23Time To Worry? Analysts Just Downgraded Their 2seventy bio, Inc. (NASDAQ:TSVT) Outlook
Aug 12Shareholder Returns
| TSVT | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -4.0% | -5.6% | -3.5% |
| 1Y | -20.3% | -1.5% | 22.1% |
Return vs Industry: TSVT underperformed the US Biotechs industry which returned -1.5% over the past year.
Return vs Market: TSVT underperformed the US Market which returned 22.1% over the past year.
Price Volatility
| TSVT volatility | |
|---|---|
| TSVT Average Weekly Movement | 10.9% |
| Biotechs Industry Average Movement | 10.7% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 17.0% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: TSVT's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: TSVT's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2021 | 274 | Chip Baird | www.2seventybio.com |
2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company’s products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma. It has a collaboration arrangement with Bristol Myers Squibb Company.
2seventy bio, Inc. Fundamentals Summary
| TSVT fundamental statistics | |
|---|---|
| Market cap | US$150.64m |
| Earnings (TTM) | -US$94.55m |
| Revenue (TTM) | US$45.62m |
3.6x
P/S Ratio-1.7x
P/E RatioIs TSVT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TSVT income statement (TTM) | |
|---|---|
| Revenue | US$45.62m |
| Cost of Revenue | US$136.35m |
| Gross Profit | -US$90.73m |
| Other Expenses | US$3.82m |
| Earnings | -US$94.55m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.83 |
| Gross Margin | -198.88% |
| Net Profit Margin | -207.25% |
| Debt/Equity Ratio | 0% |
How did TSVT perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/20 00:20 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
2seventy bio, Inc. is covered by 8 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| John Newman | Canaccord Genuity |
| Samantha Lynn Semenkow | Citigroup Inc |
| Samantha Lynn Semenkow | Citigroup Inc |